Carregant...
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab
Publisher's Note: There is a Blood Commentary on this article in this issue.
Guardat en:
| Publicat a: | Blood |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6356981/ https://ncbi.nlm.nih.gov/pubmed/30455380 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-03-839688 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|